Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling.

Roswall P, Bocci M, Bartoschek M, Li H, Kristiansen G, Jansson S, Lehn S, Sjölund J, Reid S, Larsson C, Eriksson P, Anderberg C, Cortez E, Saal LH, Orsmark-Pietras C, Cordero E, Haller BK, Häkkinen J, Burvenich IJG, Lim E, Orimo A, Höglund M, Rydén L, Moch H, Scott AM, Eriksson U, Pietras K.

Nat Med. 2018 May;24(4):463-473. doi: 10.1038/nm.4494. Epub 2018 Mar 12.

2.

Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer.

Cunha SI, Bocci M, Lövrot J, Eleftheriou N, Roswall P, Cordero E, Lindström L, Bartoschek M, Haller BK, Pearsall RS, Mulivor AW, Kumar R, Larsson C, Bergh J, Pietras K.

Cancer Res. 2015 Jun 15;75(12):2445-56. doi: 10.1158/0008-5472.CAN-14-3706. Erratum in: Cancer Res. 2016 Oct 15;76(20):6131-6132.

3.

Comparison of plasmid vaccine immunization schedules using intradermal in vivo electroporation.

Hallengärd D, Haller BK, Maltais AK, Gelius E, Nihlmark K, Wahren B, Bråve A.

Clin Vaccine Immunol. 2011 Sep;18(9):1577-81. doi: 10.1128/CVI.05045-11. Epub 2011 Jul 13.

4.

Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial.

Gudmundsdotter L, Wahren B, Haller BK, Boberg A, Edbäck U, Bernasconi D, Buttò S, Gaines H, Imami N, Gotch F, Lori F, Lisziewicz J, Sandström E, Hejdeman B.

Vaccine. 2011 Jul 26;29(33):5558-66. doi: 10.1016/j.vaccine.2011.01.064. Epub 2011 Feb 5.

PMID:
21300092
5.

A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients.

Staff C, Mozaffari F, Haller BK, Wahren B, Liljefors M.

Vaccine. 2011 Sep 9;29(39):6817-22. doi: 10.1016/j.vaccine.2010.12.063. Epub 2010 Dec 30.

PMID:
21195077
6.

Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity.

Hallengärd D, Haller BK, Petersson S, Boberg A, Maltais AK, Isaguliants M, Wahren B, Bråve A.

Vaccine. 2011 Jan 17;29(4):839-48. doi: 10.1016/j.vaccine.2010.10.083. Epub 2010 Nov 23.

PMID:
21109032
7.

Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation.

Bråve A, Gudmundsdotter L, Sandström E, Haller BK, Hallengärd D, Maltais AK, King AD, Stout RR, Blomberg P, Höglund U, Hejdeman B, Biberfeld G, Wahren B.

Vaccine. 2010 Nov 29;28(51):8203-9. doi: 10.1016/j.vaccine.2010.08.108. Epub 2010 Oct 15.

PMID:
20951666
8.

Therapeutic efficacy of a DNA vaccine targeting the endothelial tip cell antigen delta-like ligand 4 in mammary carcinoma.

Haller BK, Bråve A, Wallgard E, Roswall P, Sunkari VG, Mattson U, Hallengärd D, Catrina SB, Hellström M, Pietras K.

Oncogene. 2010 Jul 29;29(30):4276-86. doi: 10.1038/onc.2010.176. Epub 2010 May 24.

PMID:
20498640

Supplemental Content

Loading ...
Support Center